Active Ingredient History
Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor designed for the treatment of type 2 diabetes mellitus. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Empagliflozin interacts with diuretics, blood presure medicine and insulin. Jardiance reduces the risk of cardiovascular death in diabetes patients at high cardiovascular risk. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 4)
Alzheimer Disease (Phase 2)
Arrhythmias, Cardiac (Phase 4)
Ascites (Phase 1)
Atrial Fibrillation (Phase 4)
Body Weight (Phase 2)
Cardiovascular Diseases (Phase 4)
Cognitive Dysfunction (Phase 2)
Colitis, Ulcerative (Phase 2)
Coronary Artery Bypass (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Crohn Disease (Phase 1)
Diabetes Complications (Phase 4)
Diabetes, Gestational (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Lipoatrophic (Phase 3)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetic Nephropathies (Phase 4)
Diabetic Retinopathy (Phase 4)
Diuresis (Phase 2/Phase 3)
Drugs, Investigational (Phase 4)
Dumping Syndrome (Phase 4)
Dyslipidemias (Phase 3)
Fatty Liver (Phase 4)
Fibrosis (Phase 4)
Frailty (Phase 4)
Glucose Intolerance (Phase 2)
Glucose Metabolism Disorders (Phase 2)
Glycation End Products, Advanced (Phase 4)
Glycogen Storage Disease Type I (Phase 2)
Healthy Volunteers (Phase 2)
Heart Disease Risk Factors (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 4)
Heart Failure, Systolic (Phase 2)
Hepatic Insufficiency (Phase 1)
Hepatitis B, Chronic (Phase 4)
Hyperglycemia (Phase 3)
Hypertension (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Hypoglycemia (Phase 4)
Hypoglycemic Agents (Phase 4)
Hyponatremia (Phase 4)
Inappropriate ADH Syndrome (Phase 4)
Inflammatory Bowel Diseases (Phase 1)
Insulin Resistance (Phase 3)
Kidney Calculi (Phase 2)
Kidney Diseases (Phase 2)
Kidney Failure, Chronic (Phase 2)
Kidney Transplantation (Phase 4)
Liver Cirrhosis (Phase 4)
Liver Failure (Phase 4)
Metabolic Syndrome (Phase 4)
Metabolism (Phase 1)
Myocardial Infarction (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Obesity, Abdominal (Phase 4)
Pancreatic Diseases (Phase 4)
Patients (Phase 1)
Pediatrics (Phase 2)
Percutaneous Coronary Intervention (Phase 4)
Pharmacokinetics (Phase 3)
Pharmacology (Phase 3)
Physiological Effects of Drugs (Phase 1)
Polycystic Ovary Syndrome (Phase 2/Phase 3)
Prediabetic State (Phase 3)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Sarcopenia (Phase 4)
Self Efficacy (Phase 4)
Sodium-Glucose Transporter 2 Inhibitors (Phase 4)
Stroke (Phase 2)
Tricuspid Valve Insufficiency (Phase 3)
Vascular Stiffness (Phase 4)
Weight Loss (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
